07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Abcodia, Cellmid deal

The companies partnered to validate midkine ( MDK; MK) as a biomarker for cancer diagnosis using Cellmid's MK-ELISA test. The deal covers testing of multiple cancer indications, but the partners will initially focus on...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Cellmid, Fujikura Kasei Co. Ltd. deal

Cellmid said Fujikura exercised its option to license use of Cellmid's midkine ( MDK; MK) diagnostic antibodies on Fujikura's latex-based assay technology. Fujikura paid a ¥40 million ($398,800) fee. The companies will now form...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Company News

Cellmid, Fujikura Kasei Co. Ltd. deal

Fujikura received an option to license use of Cellmid's midkine ( MDK; MK) diagnostic antibodies on Fujikura's latex-based assay technology. Cellmid will receive an upfront fee and is eligible for an additional payment if...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

Cellmid preclinical data

In a mouse model of diabetic nephropathy, 2 of Cellmid's MK-Abs significantly reduced glomerular sclerosis (<20% vs. 48%, p<0.01) and interstitial volume (12% vs. 35%, p<0.01) vs. untreated controls. Mice treated with the antibodies against...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Company News

Antitope, Cellmid deal

Antitope will use its EpiScreen and Composite Human Antibody technologies to humanize Cellmid's antibody against midkine ( MDK; MK). Preclinical testing in "several disease models" is expected to begin in 4Q11. Further terms were...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

BioGenes GmbH, Cellmid sales and marketing update

Cellmid launched BioGenes' MK ELISA globally for research use to measure midkine ( MDK; MK) in blood serum. The company said MDK has been found to correlate with cancer progression and malignancy. BioGenes...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Company News

Celera, Medical Therapies deal

Celera received an exclusive, worldwide license to Medical Therapies' midkine patent portfolio to develop and commercialize lung cancer diagnostics. Midkine is a heparin-binding growth factor. Medical Therapies is developing an ELISA test to detect midkine...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

Ligand, Neurogen deal

Ligand will acquire Neurogen for about 4 million shares for a deal value of about $11 million based on Ligand's close of $2.76 on Aug. 21, the day before the deal was announced. Neurogen shareholders...
07:00 , Jun 4, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease ...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Archemix, Ribomic Inc. deal

The partners expanded a 2006 deal to give Ribomic a non-exclusive, worldwide license to use Archemix’s aptamer technology to develop aptamer therapeutics against undisclosed targets. The original deal gave Ribomic rights to use an aptamer...